Status:
COMPLETED
Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)
Lead Sponsor:
CorEvitas
Conditions:
Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER)
Eligibility:
All Genders
18-99 years
Brief Summary
This is a prospective, real-world observational study in which patients with RA who are initiating treatment with a JAK inhibitor medication will self-report disease activity and treatment satisfactio...
Detailed Description
The primary objective of this study is to analyze self-reported disease activity outcomes and treatment satisfaction measures in the real world using a bring-your-own-device approach for patients with...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A patient MUST satisfy all of the following criteria to be eligible for enrollment into the POWER study:
- Patient is currently participating in the Corrona RA Registry OR is eligible to participate and enrolls into the RA Registry prior to POWER study registration.
- Patient is willing and able to complete online weekly surveys about their RA using their own computer, tablet,or smartphone and have a valid email address.
- Patient is literate in English.
- Patients provides consent for their data to be included in ArthritisPower™ registry in addition to providing consent to participate in the POWER study itself.
- In conjunction with POWER registration:
- A Corrona RA Registry Enrollment or Follow-up visit is conducted (includes both the Provider and Subject questionnaires and most recent Lab/Imaging Results if available)
- Patient is newly prescribed\* or receives their first dose of one of the following JAK-inhibitor medications: OLUMIANT® (baricitinib), RINVOQ™ (upadacitinib), or XELJANZ / XELJANZ XR® (tofacitinib)\*\*, or any other JAK inhibitor approved during the study period.
- The decision to treat with a new therapy must precede the decision to recruit the patient into this study. Prior use of a JAK-inhibitor medication does not exclude a patient from enrollment.
- Patients switching to and from either formula of tofacitinib (Xeljanz 5 mg BID or the "once daily" XR 11 mg version) do not qualify for the POWER study.
Exclusion
Key Trial Info
Start Date :
May 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
232 Patients enrolled
Trial Details
Trial ID
NCT04512573
Start Date
May 21 2020
End Date
August 31 2022
Last Update
December 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Corrona, LLC
Waltham, Massachusetts, United States, 02451